call Toll Free (US/Canada): +1 866 658 6826 | call+1 425 320 4776 | call (UK): +44 1865 60 0662 | call (Ind): +91 9096278110 | email info(@)blueweaveconsulting.com
Home | About Us | Career | Services | Blog | Contact Us
Blueweave
Amyotrophic Lateral Sclerosis Market
Inquire Before Buying Request for Sample

Amyotrophic Lateral Sclerosis Market

Home Healthcare And Pharmaceutical Amyotrophic Lateral Sclerosis Market

Amyotrophic Lateral Sclerosis (ALS) Market - Global Size, Share, Trend Analysis, Opportunity and Forecast, 2019–2030, Segmented By Type (Sporadic ALS (SALS), Familial ALS (FALS)); By Treatment (Medication, Physical Therapy, Respiratory Therapy, Speech Therapy); By End User (Specialty Centers, Research & Academic Institutes); By Region (North America, Europe, Asia Pacific (APAC), Latin America (LATAM), Middle East and Africa (MEA))

  • Published Date: August 2024
  • Report ID: BWC24582
  • Available Format: PDF
  • Page: 400

Report Overview

Escalating ALS incidence, breakthroughs in therapeutics, enhanced research funding, and government support fostering early detection and improved patient management are expected to boost the growth of Global Amyotrophic Lateral Sclerosis (ALS) Market during the forecast period between 2024 and 2030.

Global Amyotrophic Lateral Sclerosis (ALS) Market – Industry Trends & Forecast Report, 2030

Global Amyotrophic Lateral Sclerosis (ALS) Market size was estimated at USD 902 million in 2023. During the forecast period between 2024 and 2030, Global Amyotrophic Lateral Sclerosis (ALS) Market size is expected to expand at a CAGR of 7.10% reaching a value of USD 1,456 million by 2030. Amyotrophic Lateral Sclerosis (ALS) Market across the regions is experiencing growth due to the increasing geriatric population, awareness of the disease, and its increasing incidence rate. The growth is expected to continue due to additional approvals for existing treatment options and the emergence of new drug therapies. ALS is a progressive neurodegenerative disorder that affects voluntary muscles, leading to muscle twitching, stiffness, and weakness. The disease is hereditary, with a 50% chance of inheriting a genetic mutation. Treatments like medications and stem cell therapies can help manage symptoms, prevent complications, and slow disease progression.

Amyotrophic Lateral Sclerosis Market

Amyotrophic Lateral Sclerosis (ALS) – Overview

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder affecting nerve cells in the brain and spinal cord, leading to muscle weakness, atrophy, and paralysis. Commonly known as Lou Gehrig's disease, it typically manifests with symptoms like difficulty in speaking, swallowing, and breathing. The exact cause is unknown, and there is no cure, though treatments like Riluzole and supportive therapies can slow progression and improve quality of life. ALS predominantly affects adults aged between 40 and 70 years.

Global Amyotrophic Lateral Sclerosis (ALS) Market    

Growth Drivers

Increasing Incidence of Cancer

Global Amyotrophic Lateral Sclerosis Market is driven by the increasing prevalence of cancer, with patients dying from respiratory failure within 3-5 years. The sporadic type accounts for 90-95% of cases in the United States, while the familial type accounts for the rest. The increasing geriatric population and inclination towards a sedentary lifestyle are also driving demand for targeted treatment options, further driving the market growth.

Challenges

High Cost of ALS Treatment Options

The financial burden of treating Amyotrophic Lateral Sclerosis (ALS) is significant, as it requires extensive medical care, including medications, physical therapy, and assistive devices. The cost can be overwhelming, reaching tens of thousands of dollars annually. Home modifications and round-the-clock care further exacerbate the situation. Insurance coverage often falls short, limiting access to necessary treatments and services. Developing affordable treatment options and expanding insurance coverage are crucial for ALS patients.

Impact of Escalating Geopolitical Tensions on Global Amyotrophic Lateral Sclerosis (ALS) Market    

Escalating geopolitical tensions can significantly impact Amyotrophic Lateral Sclerosis (ALS) research and patient care. Governments may prioritize defense spending, causing delays in ALS research. International collaborations may be strained, and trade restrictions could disrupt the supply chain. Patients in conflict zones may face limited access to healthcare facilities and specialized care. The psychological stress associated with geopolitical instability can worsen ALS symptoms.

Global Amyotrophic Lateral Sclerosis (ALS) Market

Segmental Information    

Global Amyotrophic Lateral Sclerosis (ALS) Market – By Type

By type, Global Amyotrophic Lateral Sclerosis (ALS) Market is split into Sporadic ALS (SALS) and Familial ALS (FALS) segments. The sporadic ALS (SALS) segment hodls a higher market share in Global Amyotrophic Lateral Sclerosis (ALS) Market. SALS accounts for the majority of ALS cases, representing approximately 90–95% of the total. It occurs randomly without a clear familial link or genetic cause, making it more prevalent than Familial ALS (FALS), which is hereditary and represents about 5–10% of cases. The high incidence of SALS drives its dominance in the ALS market.

Amyotrophic Lateral Sclerosis Market Growth

Global Amyotrophic Lateral Sclerosis (ALS) Market – By Treatment

By treatment, Global Amyotrophic Lateral Sclerosis (ALS) Market is divided into Medication, Physical Therapy, Respiratory Therapy, and Speech Therapy segments. Medication is the largest treatment segment in Global Amyotrophic Lateral Sclerosis (ALS) Market. The segment’s dominance is attributed to the significant reliance on pharmaceutical interventions to manage symptoms and slow disease progression. Medications such as Riluzole and Edaravone are widely prescribed, and ongoing research into new drugs continues to drive growth in this segment. The high cost of these medications also contributes to the larger market share compared to other therapeutic approaches like physical, respiratory, and speech therapies.

Amyotrophic Lateral Sclerosis Market Demand

Global Amyotrophic Lateral Sclerosis (ALS) Market – By Region

Regionally, Global Amyotrophic Lateral Sclerosis (ALS) Market is divided into North America, Europe, Asia Pacific (APAC), Latin America (LATAM), and Middle East and Africa (MEA). North America holds a major share of Global Amyotrophic Lateral Sclerosis (ALS) Market. The dominance is attributed to the region's advanced healthcare infrastructure, high awareness about ALS, significant investment in research and development, and the presence of key market players. The United States, in particular, plays a pivotal role due to its robust support for ALS research and extensive patient care programs.

Competitive Landscape

Key players in the highly competitive Global Amyotrophic Lateral Sclerosis (ALS) Market include Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical Co., Ltd, BrainStorm Therapeutics, Biogen Inc., Corestem, AB Science, F. Hoffmann-La Roche AG, Biohaven Pharmaceutical, Sun Pharmaceutical, and Ionis Pharmaceuticals, Inc. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

Scope of the Report

Attributes

Details

Years Considered

Historical Data – 2019–2023

Base Year – 2023

Estimated Year – 2024

Forecast Period – 2024–2030

Facts Covered

Revenue in USD Million 

Market Coverage

North America, Europe, Asia Pacific (APAC), Latin America (LATAM), Middle East and Africa (MEA)

Product/Service Segmentation

Type, Treatment, End User, Region

Key Players

Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical Co., Ltd, BrainStorm Therapeutics, Biogen Inc., Corestem, AB Science, F. Hoffmann-La Roche AG, Biohaven Pharmaceutical, Sun Pharmaceutical, Ionis Pharmaceuticals, Inc.

 

By Type

  • Sporadic ALS (SALS)

  • Familial ALS (FALS)

By Treatment

  • Medication

  • Physical Therapy

  • Respiratory Therapy

  • Speech Therapy

  • Others

By End User

  • Specialty Centers

  • Research & Academic Institutes

  • Others

By Region

  • North America

  • Europe

  • Asia Pacific (APAC)

  • Latin America (LATAM)

  • Middle East and Africa (MEA)

  1. Research Framework
    1. Research Objective
    2. Product Overview
    3. Market Segmentation
  2. Executive Summary
  3.  Global Amyotrophic Lateral Sclerosis (ALS) Market Insights
    1. Industry Value Chain Analysis
    2. DROC Analysis
      1. Growth Drivers
        1. Increasing prevalence of ALS globally
        2. Advances in medical research and technology for ALS treatment
        3. Growing healthcare expenditure and awareness
        4. Rising geriatric population susceptible to neurological disorders
      2. Restraints
        1. High cost of ALS treatment options
        2. Limited effectiveness of current therapies
        3. Stringent regulatory requirements for drug approval
      3. Opportunities
        1. Research and development initiatives for novel therapies
        2. Collaborations between pharmaceutical companies and research institutions
        3. Technological advancements in diagnostic tools for early detection
      4. Challenges
        1. Ethical concerns related to experimental ALS therapies
        2. Uneven access to ALS treatments across different regions
    3. Technological Advancements/Recent Developments
    4. Regulatory Framework
    5. Porter’s Five Forces Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of New Entrants
      4. Threat of Substitutes
      5. Intensity of Rivalry
  4.  Global Amyotrophic Lateral Sclerosis (ALS) Market: Marketing Strategies
  5. Global Amyotrophic Lateral Sclerosis (ALS) Market: Pricing Analysis
  6. Global Amyotrophic Lateral Sclerosis (ALS) Market: Geographical Analysis
  7. Global Amyotrophic Lateral Sclerosis (ALS) Market Overview
    1. Market Size & Forecast, 2019–2030
      1. By Value (USD Billion)
    2. Market Share and Forecast
      1. By Type
        1. Sporadic ALS (SALS)
        2. Familial ALS (FALS)
      2. By Treatment
        1. Medication
        2. Physical Therapy
        3. Respiratory Therapy
        4. Speech Therapy
        5. Others
      3. By End User
        1. Specialty Centers
        2. Research & Academic Institutes
        3. Others
      4. By Region
        1. North America
        2. Europe
        3. Asia Pacific (APAC)
        4. Latin America (LATAM)
        5. Middle East and Africa (MEA)
  8. North America Amyotrophic Lateral Sclerosis (ALS) Market
    1. Market Size & Forecast, 2019–2030
      1. By Value (USD Billion)
    2. Market Share & Forecast
      1. By Type
      2. By Treatment
      3. By End User
      4. By Country
        1. United States
          1. By Type
          2. By Treatment
          3. By End User
        2. Canada
          1. By Type
          2. By Treatment
          3. By End User
  9. Europe Amyotrophic Lateral Sclerosis (ALS) Market
    1. Market Size & Forecast, 2019–2030
      1. By Value (USD Billion)
    2. Market Share & Forecast
      1. By Type
      2. By Treatment
      3. By End User
      4. By Country
        1. Germany
          1. By Type
          2. By Treatment
          3. By End User
        2. United Kingdom
          1. By Type
          2. By Treatment
          3. By End User
        3. Italy
          1. By Type
          2. By Treatment
          3. By End User
        4. France
          1. By Type
          2. By Treatment
          3. By End User
        5. Spain
          1. By Type
          2. By Treatment
          3. By End User
        6. Belgium
          1. By Type
          2. By Treatment
          3. By End User
        7. Russia
          1. By Type
          2. By Treatment
          3. By End User
        8. The Netherlands
          1. By Type
          2. By Treatment
          3. By End User
        9. Rest of Europe
          1. By Type
          2. By Treatment
          3. By End User
  10. Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Market
    1. Market Size & Forecast, 2019–2030
      1. By Value (USD Billion)
    2. Market Share & Forecast
      1. By Type
      2. By Treatment
      3. By End User
      4. By Country
        1. China
          1. By Type
          2. By Treatment
          3. By End User
        2. India
          1. By Type
          2. By Treatment
          3. By End User
        3. Japan
          1. By Type
          2. By Treatment
          3. By End User
        4. South Korea
          1. By Type
          2. By Treatment
          3. By End User
        5. Australia & New Zealand
          1. By Type
          2. By Treatment
          3. By End User
        6. Indonesia
          1. By Type
          2. By Treatment
          3. By End User
        7. Malaysia
          1. By Type
          2. By Treatment
          3. By End User
        8. Singapore
          1. By Type
          2. By Treatment
          3. By End User
        9. Vietnam
          1. By Type
          2. By Treatment
          3. By End User
        10. Rest of APAC
          1. By Type
          2. By Treatment
          3. By End User
  11. Latin America Amyotrophic Lateral Sclerosis (ALS) Market
    1. Market Size & Forecast, 2019–2030
      1. By Value (USD Billion)
    2. Market Share & Forecast
      1. By Type
      2. By Treatment
      3. By End User
      4. By Country
        1. Brazil
          1. By Type
          2. By Treatment
          3. By End User
        2. Mexico
          1. By Type
          2. By Treatment
          3. By End User
        3. Argentina
          1. By Type
          2. By Treatment
          3. By End User
        4. Peru
          1. By Type
          2. By Treatment
          3. By End User
        5. Rest of LATAM
          1. By Type
          2. By Treatment
          3. By End User
  12. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Market
    1. Market Size & Forecast, 2019–2030
      1. By Value (USD Billion)
    2. Market Share & Forecast
      1. By Type
      2. By Treatment
      3. By End User
      4. By Country
        1. Saudi Arabia
          1. By Type
          2. By Treatment
          3. By End User
        2. UAE
          1. By Type
          2. By Treatment
          3. By End User
        3. Qatar
          1. By Type
          2. By Treatment
          3. By End User
        4. Kuwait
          1. By Type
          2. By Treatment
          3. By End User
        5. South Africa
          1. By Type
          2. By Treatment
          3. By End User
        6. Nigeria
          1. By Type
          2. By Treatment
          3. By End User
        7. Algeria
          1. By Type
          2. By Treatment
          3. By End User
        8. Rest of MEA
          1. By Type
          2. By Treatment
          3. By End User
  13. Competitive Landscape
    1. List of Key Players and Their Offerings
    2. Global Amyotrophic Lateral Sclerosis (ALS) Market Share Analysis, 2023
    3. Competitive Benchmarking, By Operating Parameters
    4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)
  14. Impact of Escalating Geopolitical Tensions on Global Amyotrophic Lateral Sclerosis (ALS) Market
  15. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, and SWOT Analysis)
    1. Mitsubishi Tanabe Pharma Corporation
    2. Otsuka Pharmaceutical Co., Ltd
    3. BrainStorm Therapeutics
    4. Biogen Inc.
    5. Corestem
    6. AB Science
    7. F.Hoffmann-La Roche AG
    8. Biohaven Pharmaceutical
    9. Sun Pharmaceutical
    10. Ionis Pharmaceuticals, Inc.
    11. Other Prominent Players
  16. Key Strategic Recommendations
  17. Research Methodology
    1.    Qualitative Research
      1.  Primary & Secondary Research
    2.    Quantitative Research
    3.    Market Breakdown & Data Triangulation
      1.  Secondary Research
      2.  Primary Research
    4.    Breakdown of Primary Research Respondents, By Region
    5.    Assumptions & Limitations

*Financial information of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable

 

List of Figures

 

Figure 1       Global Amyotrophic Lateral Sclerosis (ALS) Segmentation

Figure 2       Global Amyotrophic Lateral Sclerosis (ALS) Market Value Chain Analysis

Figure 3       Company Market Share Analysis, 2023

Figure 4       Global Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Figure 5       Global Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Figure 6       Global Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Figure 7       Global Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Figure 8       Global Amyotrophic Lateral Sclerosis (ALS) Market Share, By Region, By Value, 2019–2030

Figure 9       North America Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Figure 10     North America Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Figure 11     North America Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Figure 12     North America Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Figure 13     North America Amyotrophic Lateral Sclerosis (ALS) Market Share, By Country, By Value, 2019–2030

Figure 14     United States Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Figure 15     United States Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Figure 16     United States Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Figure 17     United States Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Figure 18     Canada Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Figure 19     Canada Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Figure 20     Canada Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Figure 21     Canada Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Figure 22     Europe Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Figure 23     Europe Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Figure 24     Europe Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Figure 25     Europe Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Figure 26     Europe Amyotrophic Lateral Sclerosis (ALS) Market Share, By Country, By Value, 2019–2030

Figure 27     Germany Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Figure 28     Germany Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Figure 29     Germany Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Figure 30     Germany Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Figure 31     United Kingdom Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Figure 32     United Kingdom Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Figure 33     United Kingdom Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Figure 34     United Kingdom Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Figure 35     Italy Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Figure 36     Italy Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Figure 37     Italy Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Figure 38     Italy Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Figure 39     France Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Figure 40     France Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Figure 41     France Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Figure 42     France Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Figure 43     Spain Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Figure 44     Spain Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Figure 45     Spain Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Figure 46     Spain Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Figure 47     Belgium Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Figure 48     Belgium Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Figure 49     Belgium Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Figure 50     Belgium Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Figure 51     Russia Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Figure 52     Russia Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Figure 53     Russia Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Figure 54     Russia Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Figure 55     The Netherlands Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Figure 56     The Netherlands Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Figure 57     The Netherlands Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Figure 58     The Netherlands Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Figure 59     Rest of Europe Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Figure 60     Rest of Europe Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Figure 61     Rest of Europe Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Figure 62     Rest of Europe Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Figure 63     Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Figure 64     Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Figure 65     Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Figure 66     Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Figure 67     Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Market Share, By Country, By Value, 2019–2030

Figure 68     China Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Figure 69     China Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Figure 70     China Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Figure 71     China Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Figure 72     India Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Figure 73     India Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Figure 74     India Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Figure 75     India Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Figure 76     Japan Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Figure 77     Japan Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Figure 78     Japan Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Figure 79     Japan Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Figure 80     South Korea Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Figure 81     South Korea Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Figure 82     South Korea Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Figure 83     South Korea Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Figure 84     Australia & New Zealand Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Figure 85     Australia & New Zealand Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Figure 86     Australia & New Zealand Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Figure 87     Australia & New Zealand Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Figure 88     Indonesia Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Figure 89     Indonesia Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Figure 90     Indonesia Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Figure 91     Indonesia Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Figure 92     Malaysia Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Figure 93     Malaysia Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Figure 94     Malaysia Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Figure 95     Malaysia Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Figure 96     Singapore Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Figure 97     Singapore Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Figure 98     Singapore Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Figure 99     Singapore Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Figure 100   Vietnam Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Figure 101   Vietnam Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Figure 102   Vietnam Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Figure 103   Vietnam Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Figure 104   Rest of APAC Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Figure 105   Rest of APAC Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Figure 106   Rest of APAC Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Figure 107   Rest of APAC Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Figure 108   Latin America Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Figure 109   Latin America Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Figure 110   Latin America Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Figure 111   Latin America Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Figure 112   Latin America Amyotrophic Lateral Sclerosis (ALS) Market Share, By Country, By Value, 2019–2030

Figure 113   Brazil Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Figure 114   Brazil Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Figure 115   Brazil Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Figure 116   Brazil Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Figure 117   Mexico Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Figure 118   Mexico Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Figure 119   Mexico Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Figure 120   Mexico Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Figure 121   Argentina Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Figure 122   Argentina Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Figure 123   Argentina Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Figure 124   Argentina Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Figure 125   Peru Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Figure 126   Peru Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Figure 127   Peru Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Figure 128   Peru Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Figure 129   Rest of LATAM Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Figure 130   Rest of LATAM Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Figure 131   Rest of LATAM Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Figure 132   Rest of LATAM Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Figure 133   Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Figure 134   Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Figure 135   Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Figure 136   Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Figure 137   Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Share, By Country, By Value, 2019–2030

Figure 138   Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Figure 139   Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Figure 140   Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Figure 141   Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Figure 142   UAE Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Figure 143   UAE Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Figure 144   UAE Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Figure 145   UAE Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Figure 146   Qatar Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Figure 147   Qatar Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Figure 148   Qatar Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Figure 149   Qatar Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Figure 150   Kuwait Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Figure 151   Kuwait Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Figure 152   Kuwait Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Figure 153   Kuwait Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Figure 154   South Africa Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Figure 155   South Africa Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Figure 156   South Africa Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Figure 157   South Africa Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Figure 158   Nigeria Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Figure 159   Nigeria Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Figure 160   Nigeria Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Figure 161   Nigeria Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Figure 162   Algeria Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Figure 163   Algeria Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Figure 164   Algeria Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Figure 165   Algeria Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Figure 166   Rest of MEA Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Figure 167   Rest of MEA Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Figure 168   Rest of MEA Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Figure 169   Rest of MEA Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

 

List of Tables

 

Table 1        Global Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Table 2 Global Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Table 3 Global Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Table 4 Global Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Table 5 Global Amyotrophic Lateral Sclerosis (ALS) Market Share, By Region, By Value, 2019–2030

Table 6 North America Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Table 7 North America Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Table 8 North America Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Table 9 North America Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Table 10      North America Amyotrophic Lateral Sclerosis (ALS) Market Share, By Country, By Value, 2019–2030

Table 11      United States Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Table 12      United States Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Table 13      United States Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Table 14      United States Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Table 15      Canada Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Table 16      Canada Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Table 17      Canada Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Table 18      Canada Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Table 19      Europe Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Table 20      Europe Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Table 21      Europe Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Table 22      Europe Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Table 23      Europe Amyotrophic Lateral Sclerosis (ALS) Market Share, By Country, By Value, 2019–2030

Table 24      Germany Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Table 25      Germany Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Table 26      Germany Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Table 27      Germany Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Table 28      United Kingdom Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Table 29      United Kingdom Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Table 30      United Kingdom Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Table 31      United Kingdom Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Table 32      Italy Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Table 33      Italy Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Table 34      Italy Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Table 35      Italy Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Table 36      France Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Table 37      France Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Table 38      France Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Table 39      France Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Table 40      Spain Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Table 41      Spain Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Table 42      Spain Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Table 43      Spain Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Table 44      Belgium Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Table 45      Belgium Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Table 46      Belgium Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Table 47      Belgium Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Table 48      Russia Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Table 49      Russia Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Table 50      Russia Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Table 51      Russia Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Table 52      The Netherlands Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Table 53      The Netherlands Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Table 54      The Netherlands Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Table 55      The Netherlands Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Table 56      Rest of Europe Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Table 57      Rest of Europe Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Table 58      Rest of Europe Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Table 59      Rest of Europe Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Table 60      Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Table 61      Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Table 62      Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Table 63      Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Table 64      Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Market Share, By Country, By Value, 2019–2030

Table 65      China Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Table 66      China Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Table 67      China Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Table 68      China Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Table 69      India Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Table 70      India Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Table 71      India Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Table 72      India Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Table 73      Japan Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Table 74      Japan Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Table 75      Japan Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Table 76      Japan Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Table 77      South Korea Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Table 78      South Korea Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Table 79      South Korea Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Table 80      South Korea Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Table 81      Australia & New Zealand Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Table 82      Australia & New Zealand Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Table 83      Australia & New Zealand Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Table 84      Australia & New Zealand Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Table 85      Indonesia Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Table 86      Indonesia Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Table 87      Indonesia Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Table 88      Indonesia Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Table 89      Malaysia Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Table 90      Malaysia Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Table 91      Malaysia Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Table 92      Malaysia Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Table 93      Singapore Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Table 94      Singapore Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Table 95      Singapore Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Table 96      Singapore Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Table 97      Vietnam Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Table 98      Vietnam Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Table 99      Vietnam Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Table 100    Vietnam Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Table 101    Rest of APAC Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Table 102    Rest of APAC Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Table 103    Rest of APAC Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Table 104    Rest of APAC Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Table 105    Latin America Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Table 106    Latin America Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Table 107    Latin America Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Table 108    Latin America Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Table 109    Latin America Amyotrophic Lateral Sclerosis (ALS) Market Share, By Country, By Value, 2019–2030

Table 110    Brazil Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Table 111    Brazil Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Table 112    Brazil Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Table 113    Brazil Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Table 114    Mexico Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Table 115    Mexico Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Table 116    Mexico Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Table 117    Mexico Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Table 118    Argentina Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Table 119    Argentina Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Table 120    Argentina Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Table 121    Argentina Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Table 122    Peru Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Table 123    Peru Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Table 124    Peru Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Table 125    Peru Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Table 126    Rest of LATAM Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Table 127    Rest of LATAM Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Table 128    Rest of LATAM Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Table 129    Rest of LATAM Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Table 130    Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Table 131    Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Table 132    Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Table 133    Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Table 134    Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Share, By Country, By Value, 2019–2030

Table 135    Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Table 136    Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Table 137    Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Table 138    Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Table 139    UAE Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Table 140    UAE Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Table 141    UAE Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Table 142    UAE Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Table 143    Qatar Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Table 144    Qatar Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Table 145    Qatar Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Table 146    Qatar Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Table 147    Kuwait Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Table 148    Kuwait Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Table 149    Kuwait Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Table 150    Kuwait Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Table 151    South Africa Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Table 152    South Africa Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Table 153    South Africa Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Table 154    South Africa Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Table 155    Nigeria Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Table 156    Nigeria Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Table 157    Nigeria Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Table 158    Nigeria Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Table 159    Algeria Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Table 160    Algeria Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Table 161    Algeria Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Table 162    Algeria Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Table 163    Rest of MEA Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030

Table 164    Rest of MEA Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030

Table 165    Rest of MEA Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030

Table 166    Rest of MEA Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030

Table 167    Mitsubishi Tanabe Pharma Corporation Company Overview

Table 168    Mitsubishi Tanabe Pharma Corporation Financial Overview

Table 169    Otsuka Pharmaceutical Co., Ltd Company Overview

Table 170    Otsuka Pharmaceutical Co., Ltd Financial Overview

Table 171    BrainStorm Therapeutics Company Overview

Table 172    BrainStorm Therapeutics Financial Overview

Table 173    Biogen Inc. Company Overview

Table 174    Biogen Inc. Financial Overview

Table 175    Corestem Company Overview

Table 176    Corestem Financial Overview

Table 177    AB Science Company Overview

Table 178    AB Science Financial Overview

Table 179    F.Hoffmann-La Roche AG Company Overview

Table 180    F.Hoffmann-La Roche AG Financial Overview

Table 181    Biohaven Pharmaceutical Company Overview

Table 182    Biohaven Pharmaceutical Financial Overview

Table 183    Sun Pharmaceutical Company Overview

Table 184    Sun Pharmaceutical Financial Overview

Table 185    Ionis Pharmaceuticals, Inc.  Company Overview

Table 186    Ionis Pharmaceuticals, Inc.  Financial Overview

Market Segmentation

No data available
No data available

To request a free sample copy of this report, please complete the form below.

We value your investment and offer free customization with every report to fulfil your exact research needs.

Note: Please share the corporate email address for faster response

This website is secure and your personal details are safe.

Frequently Asked Questions (FAQs):

Ans: Global Amyotrophic Lateral Sclerosis (ALS) Market size by value was estimated at USD 902 million in 2023.
Ans: Global Amyotrophic Lateral Sclerosis (ALS) Market by value is expected to grow at a CAGR of 7.10% during the forecast period between 2024 and 2030.
Ans: Global Amyotrophic Lateral Sclerosis (ALS) Market size is forecast to reach a value of USD 1,456 million by 2030.
Ans: Growth of Global Amyotrophic Lateral Sclerosis (ALS) Market is primarily driven by escalating ALS incidence, breakthroughs in therapeutics, enhanced research funding, and governmental support, fostering early detection and improved patient management.
Ans: The sporadic ALS (SALS) segment accounts for the highest market share in Global Amyotrophic Lateral Sclerosis (ALS) Market by type.
Ans: Key players in Global Amyotrophic Lateral Sclerosis (ALS) Market include Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical Co., Ltd, BrainStorm Therapeutics, Biogen Inc., Corestem, AB Science, F. Hoffmann-La Roche AG, Biohaven Pharmaceutical, Sun Pharmaceutical, and Ionis Pharmaceuticals, Inc. 
array(1) {
  ["__ci_last_regenerate"]=>
  int(1734902439)
}